Liposomal drug delivery to manage nontuberculous mycobacterial pulmonary disease and other chronic lung infections
- PMID: 34289985
- PMCID: PMC9488898
- DOI: 10.1183/16000617.0010-2021
Liposomal drug delivery to manage nontuberculous mycobacterial pulmonary disease and other chronic lung infections
Abstract
Nontuberculous mycobacterial (NTM) pulmonary disease is a chronic respiratory infection associated with declining lung function, radiological deterioration and significantly increased morbidity and mortality. Patients often have underlying lung conditions, particularly bronchiectasis and COPD. NTM pulmonary disease is difficult to treat because mycobacteria can evade host defences and antimicrobial therapy through extracellular persistence in biofilms and sequestration into macrophages. Management of NTM pulmonary disease remains challenging and outcomes are often poor, partly due to limited penetration of antibiotics into intracellular spaces and biofilms. Efficient drug delivery to the site of infection is therefore a key objective of treatment, but there is high variability in lung penetration by antibiotics. Inhalation is the most direct route of delivery and has demonstrated increased efficacy of antibiotics like amikacin compared with systemic administration. Liposomes are small, artificial, enclosed spherical vesicles, in which drug molecules can be encapsulated to provide controlled release, with potentially improved pharmacokinetics and reduced toxicity. They are especially useful for drugs where penetration of cell membranes is essential. Inhaled delivery of liposomal drug solutions can therefore facilitate direct access to macrophages in the lung where the infecting NTM may reside. A range of liposomal drugs are currently being evaluated in respiratory diseases.
Copyright ©The authors 2021.
Conflict of interest statement
Conflict of interest: J.D. Chalmers reports grants and personal fees from AstraZeneca, Conflict of interest: Boehringer Ingelheim, GlaxoSmithKline and Insmed; grants from Gilead Sciences and Grifols; and personal fees from Chiesi, Novartis and Zambon, outside the submitted work. Conflict of interest: J. van Ingen reports advisory board membership from Insmed, outside the submitted work. Conflict of interest: R. van der Laan is an employee of Insmed. Conflict of interest: J-L. Herrmann has nothing to disclose.
Figures
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical